BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34681840)

  • 1. PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation.
    Spirina L; Avgustinovich A; Afanas'ev S; Volkov M; Dobrodeev A; Cheremisina O; Kostromitsky D
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.
    Spirina LV; Avgustinovich AV; Afanas'ev SG; Kondakova IV; Volkov MY; Dobrodeev AY; Boronkina AI
    Bull Exp Biol Med; 2020 Nov; 170(1):75-78. PubMed ID: 33231797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer.
    Li H; Zhao S; Shen L; Wang P; Liu S; Ma Y; Liang Z; Wang G; Lv J; Qiu W
    Aging (Albany NY); 2021 Apr; 13(10):13626-13643. PubMed ID: 34091441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.
    Song L; Liu S; Zhao S
    Bioengineered; 2022 Apr; 13(4):11240-11257. PubMed ID: 35485300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells.
    Tong G; Cheng B; Li J; Wu X; Nong Q; He L; Li X; Li L; Wang S
    Cancer Med; 2019 Nov; 8(16):7044-7054. PubMed ID: 31557409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and Content of Protein LC3B in Gastric Cancer Tissue, Relationship with Expression of mTOR, AMPK in Gastric Cancer Tissue and HER2 and PD-L1 Status of the Tumor.
    Spirina LV; Avgustinovich AV; Afanas'ev SG; Volkov MY; Kondakova IV
    Bull Exp Biol Med; 2021 Dec; 172(2):202-205. PubMed ID: 34855092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
    Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
    Wu L; Cai S; Deng Y; Zhang Z; Zhou X; Su Y; Xu D
    Int Immunopharmacol; 2021 May; 94():107443. PubMed ID: 33581579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
    Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
    Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
    Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
    Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
    Zhang C; Li Z; Xu L; Che X; Wen T; Fan Y; Li C; Wang S; Cheng Y; Wang X; Qu X; Liu Y
    BMC Cancer; 2018 Apr; 18(1):462. PubMed ID: 29690901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma.
    Sughayer MA; Dabbagh TZ; Battah AH
    Appl Immunohistochem Mol Morphol; 2020; 28(10):748-754. PubMed ID: 32205740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
    Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
    Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
    Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
    Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
    Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
    Dong Z; Liao B; Shen W; Sui C; Yang J
    Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
    Yuan J; Zhang J; Zhu Y; Li N; Tian T; Li Y; Li Y; Li Z; Lai Y; Gao J; Shen L
    Oncotarget; 2016 Jun; 7(26):39671-39679. PubMed ID: 27191996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
    Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
    Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.